FDA Inspection 1269601 — GSK LLC (GlaxoSmithKline)

GSK LLC (GlaxoSmithKline) — FEI 3006810568

The FDA completed an inspection of GSK LLC (GlaxoSmithKline) on Oct 21, 2025 in Collegeville, PA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.

Inspection details

Classification
No Action Indicated (NAI)
End Date
Oct 21, 2025
Fiscal Year
2026
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Collegeville, PA (United States)

Additional details

Sponsor, Contract Research Organization

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.